AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
09 Maio 2023 - 9:50AM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”), an immuno-pharma
company focused on the research and development of therapeutics to
treat multiple types of cancers, immune disorders, and viral
diseases — including COVID-19, the disease caused by the SARS-CoV-2
virus — announced today that management will host a conference call
and webcast to discuss the Company’s Q1 2023 operational and
financial results on Tuesday, May 16, 2023 at 8:30 AM
ET.
The call will be hosted by members of AIM’s
leadership team, Thomas K. Equels, Chief Executive Officer and
Christopher McAleer, PhD, Scientific Officer. Interested
participants and investors may access the conference call by
dialing (877) 407-9219 (domestic) or (201) 689-8852 (international)
and referencing the AIM ImmunoTech Conference Call. The live
webcast will be accessible on the Events page of the Investors
section of the Company’s website, aimimmuno.com, and will be
archived for 90 days following the live event. About
AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.For more information,
please visit aimimmuno.com and connect with the Company
on Twitter, LinkedIn, and Facebook.Investor
Contact:
JTC Team, LLCJenene Thomas(833) 475-8247AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024